<DOC>
	<DOCNO>NCT02101190</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( PK ) BIA 9-1067 patient moderate chronic hepatic impairment match healthy subject .</brief_summary>
	<brief_title>Pharmacokinetics BIA 9-1067 Subjects With Hepatic Impairment</brief_title>
	<detailed_description>This open-label , single-dose , parallel-group , in-patient , nonrandomized study conduct 8 patient moderate chronic hepatic impairment 8 healthy match subject match origin , age , sex , weight , smoke habit . Each hepatic impaired patient match healthy subject participate study approximately one month , include 21-day screening period 4-day/4-night inpatient period . The inpatient period cover period Day -1 Day 4 morning ( 72 hour administration ) . The final study evaluation perform subject morning day discharge , Day 4 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>All subject : 1 . Men nonlactating nonpregnant woman , 2 . Women nonchildbearing potential ( WONCBP ) , expect surgically sterile ( hysterectomy , oophorectomy , tubal ligation ) postmenopausal &gt; 1 year , 3 . Women childbearing potential ( WOCBP ) , expect use acceptable method contraception ( sexual abstinence , implant , IUD , injectables , vasectomise partner association condom + spermicide , diaphragm + spermicide , diaphragm + condom ) period least 1 month dose administration . WOCBP expect negative pregnancy test ( serum betahuman chorionic gonadotropin [ βHCG ] ) result within 48 hour start first IMP administration . Hormonal contraceptive allow effect BIA 91067 metabolism oral contraceptive vice versa yet know , 4 . Male subject plan father child donate sperm , study 1 month end study . Acceptable method contraception comprise condom medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive last 2 month ) , 5 . Expected high probability compliance completion study , Hepatic Impaired Patients : 6 . Aged 18 65 year , 7 . Body weight ≥ 50 kg , 8 . Child Pugh class B ( score 7 , 8 9 ) calculate accord ChildPugh classification base history , physical examination , laboratory test result screen Day 1 , 9 . Hepatic impairment associate underlying systemic disease , 10 . Medications necessary management hepatic disease concomitant condition permit therapeutic regimen stable least 7 day BIA 91067 administration interfere kinetics test product , Matched Healthy Subjects : 11 . Aged 18 65 year , 12 . Body weight ≥ 50 kg , 13 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead electrocardiogram ( ECG ) . Alanine aminotransferase ( ALT ) creatinine level strictly within normal range eligibility . 1 . Presence history disorder may prevent successful completion study . Allergies Adverse Drug Reactions 2 . History multiple and/or severe allergy drug food history anaphylactic reaction . 3 . Known suspected allergy adverse drug reaction trial product relate product ( e.g tolcapone entacapone ) . 4 . Positive pregnancy test result ( serum BetaHCG ) woman childbearing potential . 5 . Consumption caffeinecontaining product ( eg , coffee , tea , chocolate , cola ) , grapefruit , grapefruitcontaining product , alcoholic beverage 48 hour study day 1 end inpatient confinement period . 6 . Involvement investigational study type within 30 day BIA 91067 administration . 7 . Donation blood within 90 day study day 1 . 8 . Evidence unstable clinically significant disease impair hepatic function ( e.g. , cardiovascular , cerebrovascular , respiratory , renal disease , serious disorder currently require physician 's care ) . 9 . Recent history presence disorder may interfere absorption , distribution , metabolism , excretion BIA 91067 ( except hepatic impairment ) . 10 . Patients severe encephalopathy . 11 . Acute exacerbation hepatic disease , indicate worsen clinical and/or laboratory sign hepatic impairment , within 2 week BIA 91067 administration ( eg , advanced ascites , infection ascites , fever , hepatic encephalopathy active gastrointestinal bleeding ( hematemesis , melena ) , significant abdominal pain , persistent nausea vomiting , worsen total bilirubin prothrombin time &gt; 50 % ) . 12 . Presence hepatocellular carcinoma , acute hepatic disease cause infection drug toxicity . 13 . Presence surgically create portalsystemic shunt . 14 . Positive serologic find human immunodeficiency virus ( HIV ) antibody . 15 . Prescription overthecounter ( OTC ) medication dos must stable 7 day IMP administration . Healthy Matched Subjects : 16 . History alcoholism excessive daily alcohol consumption within past year . Excessive alcohol consumption regard average weekly intake 14 unit woman 21 unit men ( 1 unit alcohol = 8 10 g approximately equivalent 1 glass wine 250 mL beer standard measure spirit ) . 17 . Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 18 . Any clinically important deviation normal limit physical examination , vital sign , 12lead ECGs . 19 . Acute disease state ( e.g. , nausea , vomit , fever , diarrhea ) within 7 day study day 1 . 20 . Positive serologic finding HIV antibody , hepatitis B surface antigen ( Hbs Ag ) , and/or hepatitis C virus ( HCV ) antibody . 21 . Recent history presence disorder may interfere absorption , distribution , metabolism , excretion BIA 91067 . 22 . Use prescription drug within 30 day IMP administration . 23 . Use OTC drug include herbal supplement ( except occasional use acetaminophen vitamin ≤100 % recommend daily allowance ) within 14 day study day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>BIA 9-1067</keyword>
	<keyword>Opicapone</keyword>
	<keyword>catechol-O-methyltransferase ( COMT )</keyword>
</DOC>